COVID - 19
Conditions
Keywords
ATMP
Brief summary
A Phase II safety and tolerability study of expanded gamma delta T cell lymphocytes (TCB008) in patients diagnosed with COVID-19.
Detailed description
The aim of this Phase II study is to evaluate the safety and tolerability of ex-vivo expanded gamma delta T-cells (TCB008) manufactured from a single allogeneic unmatched or partially, randomly matched, unrelated donor, in patients with COVID-19. The trial is designed to identify an optimal, safe dose of allogeneic γδ T cells in a population of patients with COVID-19. There will be 4 patient Cohorts. Cohorts 1 - 3 will receive a pre-defined dosing schedule, with Cohort 4 being treated with a dose selected upon completion of the first 3 Cohorts. In order to investigate immunogenicity assessment/sensitisation effects, patients in the expansion cohort who do not experience adverse reactions meeting dose limiting toxicity (DLT) criteria after the first administration will receive re-infusion with the same dose on Day 10 after the first infusion.
Interventions
DRUGTCB008
administration of gamma delta T cells by IV bolus injection
Sponsors
TC Biopharm
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
open-label, safety and tolerability, escalating dose, single arm study
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF); \- willingness and capability to complete all the study procedures 2. Age 18-65 years (inclusive) at the time of signing ICF 3. Any gender 4. Patients with a positive diagnosis of COVID-19 either identified in the community as at risk of progression of disease or * already hospitalized with new changes on CXR or CT scan compatible with COVID19, or * patients requiring supplemental oxygen, but for whom dexamethasone is not yet indicated according to current standard of care recommendations. The product would be indicated for patients categorized as per the WHO ordinal scale 2,3 or 4: i.e., ambulatory (or community identified) patients with limitations of activity, judged as at risk for progression of disease, as well as hospitalized patients not yet requiring oxygen therapy or receiving non-invasive low flow oxygen therapy, which does not yet indicate the need to commence dexamethasone therapy.
Exclusion criteria
1. Patients requiring high-flow oxygen therapy and/or dexamethasone according to the current standard of care. 2. Patients suffering from severe cognitive impairment or mental illness 3. Pregnant and/or lactating women 4. Patients participating in other CTIMP clinical studies at the same time 5. Active autoimmune disease or Graft versus Host Disease (GVHD) 6. Patients with any major comorbidity (e.g., diabetes, cardiovascular and pulmonary diseases, malignancies on active treatment) unless their pre-morbid Karnofsky performance status was ≥ 80% 7. Patients with documented history of immunological disorders 8. Immunocompromised patients defined as those with human immunodeficiency virus infection with a CD4 cell count of less than 200 per microliter or uncontrolled viremia, prolonged use of glucocorticoids or other immunomodulating medications, a history of bone marrow or organ transplantation 9. ALT / AST\> 5 times the upper limit of the normal 10. Neutrophils \<500 / mm3 11. Platelets \<50.000 / mm3 12. Patients known or suspected to have sensitivity against mouse immunoglobulins or iron-dextran.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Assessment of treatment emergent adverse events (AEs) - Safety | 30 and 90 days after IMP administration | Safety of IMP assessed by incidence of treatment-emergent adverse events (AEs) per patient, graded by Common Terminology Criteria for Adverse Events (CTCAE) V5.0 |
| Incidence of dose-limiting toxicities (DLTs) - Tolerability | 30 and 90 days after IMP administration | Tolerability of IMP assessed by incidence of dose-limiting toxicities (DLT's) graded by Common Terminology Criteria for Adverse Events (CTCAE) V5.0 |
| Establish Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) - Tolerability | Approx 1 year | Tolerability of IMP assessed by incidence of dose-limiting toxicities (DLT's) graded by Common Terminology Criteria for Adverse Events (CTCAE) V5.0 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Persistence of gamma delta T cells | Approx 1 year | Assessment of the persistence of gamma delta T cells in the peripheral blood os dosed patients using flow cytometry |
| Phenotype of gamma delta T cells | Approx 1 year | Assessment of the phenotype of gamma delta T cells in the peripheral blood of dosed patients using flow cytometry |
Countries
United Kingdom
Outcome results
None listed